In prostate cancer, it is shown that CCL5-derived from MSCs and cancer cells, through suppressing the nuclear translocation of androgen receptors, increases the metastatic potential of cancer cells due to inhibiting androgen receptor signaling (169). The gene discussed is AR; the disease is prostate cancer.